메뉴 건너뛰기




Volumn 97, Issue 1, 2015, Pages 16-26

Biological effects of interleukin-6: Clinical applications in autoimmune diseases and cancers

Author keywords

Autoimmunity; Cancer; Cytokine; IL 6; Signaling pathways; Therapy

Indexed keywords

CHOLESTEROL; CLAZAKIZUMAB; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; LIPID; OLOKIZUMAB; SARILUMAB; SILTUXIMAB; SIRUKUMAB; TOCILIZUMAB; ANTINEOPLASTIC ANTIMETABOLITE; IL6 PROTEIN, HUMAN; IL6R PROTEIN, HUMAN; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR PROTEIN;

EID: 84939571585     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2015.06.009     Document Type: Note
Times cited : (65)

References (113)
  • 1
    • 0022499547 scopus 로고
    • Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin
    • T. Hirano, K. Yasukawa, H. Harada, T. Taga, Y. Watanabe, T. Matsuda, and et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin Nature 324 1986 73 76
    • (1986) Nature , vol.324 , pp. 73-76
    • Hirano, T.1    Yasukawa, K.2    Harada, H.3    Taga, T.4    Watanabe, Y.5    Matsuda, T.6
  • 2
    • 17644368573 scopus 로고    scopus 로고
    • Interleukin-6: From basic science to medicine - 40 years in immunology
    • T. Kishimoto Interleukin-6: from basic science to medicine - 40 years in immunology Annu. Rev. Immunol. 23 2005 1 21
    • (2005) Annu. Rev. Immunol. , vol.23 , pp. 1-21
    • Kishimoto, T.1
  • 5
    • 0029863504 scopus 로고    scopus 로고
    • The function of the soluble interleukin 6 (IL-6) receptor in vivo: Sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6
    • M. Peters, S. Jacobs, M. Ehlers, P. Vollmer, J. Mullberg, E. Wolf, and et al. The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6 J. Exp. Med. 183 1996 1399 1406
    • (1996) J. Exp. Med. , vol.183 , pp. 1399-1406
    • Peters, M.1    Jacobs, S.2    Ehlers, M.3    Vollmer, P.4    Mullberg, J.5    Wolf, E.6
  • 8
    • 84906535154 scopus 로고    scopus 로고
    • The IL-23-IL-17 immune axis: From mechanisms to therapeutic testing
    • S.L. Gaffen, R. Jain, A.V. Garg, and D.J. Cua The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing Nat. Rev. Immunol. 14 2014 585 600
    • (2014) Nat. Rev. Immunol. , vol.14 , pp. 585-600
    • Gaffen, S.L.1    Jain, R.2    Garg, A.V.3    Cua, D.J.4
  • 9
    • 33646577466 scopus 로고    scopus 로고
    • Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells
    • E. Bettelli, Y. Carrier, W. Gao, T. Korn, T.B. Strom, M. Oukka, and et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells Nature 441 2006 235 238
    • (2006) Nature , vol.441 , pp. 235-238
    • Bettelli, E.1    Carrier, Y.2    Gao, W.3    Korn, T.4    Strom, T.B.5    Oukka, M.6
  • 10
    • 57349083145 scopus 로고    scopus 로고
    • Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses
    • M. Fujimoto, S. Serada, M. Mihara, Y. Uchiyama, H. Yoshida, N. Koike, and et al. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses Arthritis Rheum. 58 2008 3710 3719
    • (2008) Arthritis Rheum. , vol.58 , pp. 3710-3719
    • Fujimoto, M.1    Serada, S.2    Mihara, M.3    Uchiyama, Y.4    Yoshida, H.5    Koike, N.6
  • 11
    • 0037363585 scopus 로고    scopus 로고
    • Immunoregulation in the tissues by gammadelta T cells
    • A. Hayday, and R. Tigelaar Immunoregulation in the tissues by gammadelta T cells Nat. Rev. Immunol. 3 2003 233 242
    • (2003) Nat. Rev. Immunol. , vol.3 , pp. 233-242
    • Hayday, A.1    Tigelaar, R.2
  • 12
    • 77954143695 scopus 로고    scopus 로고
    • Innate IL-17-producing cells: The sentinels of the immune system
    • D.J. Cua, and C.M. Tato Innate IL-17-producing cells: the sentinels of the immune system Nat. Rev. Immunol. 10 2010 479 489
    • (2010) Nat. Rev. Immunol. , vol.10 , pp. 479-489
    • Cua, D.J.1    Tato, C.M.2
  • 13
    • 80052734905 scopus 로고    scopus 로고
    • Interleukin-17 accelerates allograft rejection by suppressing regulatory T cell expansion
    • S. Itoh, N. Kimura, R.C. Axtell, J.B. Velotta, Y. Gong, X. Wang, and et al. Interleukin-17 accelerates allograft rejection by suppressing regulatory T cell expansion Circulation 124 2011 S187 S196
    • (2011) Circulation , vol.124 , pp. S187-S196
    • Itoh, S.1    Kimura, N.2    Axtell, R.C.3    Velotta, J.B.4    Gong, Y.5    Wang, X.6
  • 14
    • 79960119130 scopus 로고    scopus 로고
    • Differentiation, phenotype, and function of interleukin-17-producing human Vgamma9Vdelta2 T cells
    • N. Caccamo, C. La Mendola, V. Orlando, S. Meraviglia, M. Todaro, G. Stassi, and et al. Differentiation, phenotype, and function of interleukin-17-producing human Vgamma9Vdelta2 T cells Blood 118 2011 129 138
    • (2011) Blood , vol.118 , pp. 129-138
    • Caccamo, N.1    La Mendola, C.2    Orlando, V.3    Meraviglia, S.4    Todaro, M.5    Stassi, G.6
  • 15
    • 81455135808 scopus 로고    scopus 로고
    • Prostaglandin I(2)promotes the development of IL-17-producing gammadelta T cells that associate with the epithelium during allergic lung inflammation
    • Z. Jaffar, M.E. Ferrini, P.K. Shaw, G.A. FitzGerald, and K. Roberts Prostaglandin I(2)promotes the development of IL-17-producing gammadelta T cells that associate with the epithelium during allergic lung inflammation J. Immunol. 187 2011 5380 5391
    • (2011) J. Immunol. , vol.187 , pp. 5380-5391
    • Jaffar, Z.1    Ferrini, M.E.2    Shaw, P.K.3    FitzGerald, G.A.4    Roberts, K.5
  • 16
    • 84897952509 scopus 로고    scopus 로고
    • Treg functional stability and its responsiveness to the microenvironment
    • J. Barbi, D. Pardoll, and F. Pan Treg functional stability and its responsiveness to the microenvironment Immunol. Rev. 259 2014 115 139
    • (2014) Immunol. Rev. , vol.259 , pp. 115-139
    • Barbi, J.1    Pardoll, D.2    Pan, F.3
  • 17
    • 77954096689 scopus 로고    scopus 로고
    • IL-6: Regulator of Treg/Th17 balance
    • A. Kimura, and T. Kishimoto IL-6: regulator of Treg/Th17 balance Eur. J. Immunol. 40 2010 1830 1835
    • (2010) Eur. J. Immunol. , vol.40 , pp. 1830-1835
    • Kimura, A.1    Kishimoto, T.2
  • 18
    • 0028675983 scopus 로고
    • Interleukin-6 is required in vivo for the regulation of stem cells and committed progenitors of the hematopoietic system
    • A. Bernad, M. Kopf, R. Kulbacki, N. Weich, G. Koehler, and J.C. Gutierrez-Ramos Interleukin-6 is required in vivo for the regulation of stem cells and committed progenitors of the hematopoietic system Immunity 1 1994 725 731
    • (1994) Immunity , vol.1 , pp. 725-731
    • Bernad, A.1    Kopf, M.2    Kulbacki, R.3    Weich, N.4    Koehler, G.5    Gutierrez-Ramos, J.C.6
  • 19
    • 81255189474 scopus 로고    scopus 로고
    • IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development
    • D. Reynaud, E. Pietras, K. Barry-Holson, A. Mir, M. Binnewies, M. Jeanne, and et al. IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development Cancer Cell 20 2011 661 673
    • (2011) Cancer Cell , vol.20 , pp. 661-673
    • Reynaud, D.1    Pietras, E.2    Barry-Holson, K.3    Mir, A.4    Binnewies, M.5    Jeanne, M.6
  • 20
    • 84864744709 scopus 로고    scopus 로고
    • Context-specific roles for paracrine IL-6 in lymphomagenesis
    • L.A. Gilbert, and M.T. Hemann Context-specific roles for paracrine IL-6 in lymphomagenesis Genes Dev. 26 2012 1758 1768
    • (2012) Genes Dev. , vol.26 , pp. 1758-1768
    • Gilbert, L.A.1    Hemann, M.T.2
  • 21
    • 77949322552 scopus 로고    scopus 로고
    • Autoimmune disease in Lyn-deficient mice is dependent on an inflammatory environment established by IL-6
    • E. Tsantikos, S.A. Oracki, C. Quilici, G.P. Anderson, D.M. Tarlinton, and M.L. Hibbs Autoimmune disease in Lyn-deficient mice is dependent on an inflammatory environment established by IL-6 J. Immunol. 184 2010 1348 1360
    • (2010) J. Immunol. , vol.184 , pp. 1348-1360
    • Tsantikos, E.1    Oracki, S.A.2    Quilici, C.3    Anderson, G.P.4    Tarlinton, D.M.5    Hibbs, M.L.6
  • 22
    • 0029999725 scopus 로고    scopus 로고
    • Is IL-6 both a cytokine and a neurotrophic factor?
    • J.A. Wagner Is IL-6 both a cytokine and a neurotrophic factor? J. Exp. Med. 183 1996 2417 2419
    • (1996) J. Exp. Med. , vol.183 , pp. 2417-2419
    • Wagner, J.A.1
  • 23
    • 0032534730 scopus 로고    scopus 로고
    • IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: Roles of IL-6 in the activation and differentiation of autoreactive T cells
    • E.B. Samoilova, J.L. Horton, B. Hilliard, T.S. Liu, and Y. Chen IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells J. Immunol. 161 1998 6480 6486
    • (1998) J. Immunol. , vol.161 , pp. 6480-6486
    • Samoilova, E.B.1    Horton, J.L.2    Hilliard, B.3    Liu, T.S.4    Chen, Y.5
  • 24
    • 84863803849 scopus 로고    scopus 로고
    • B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells
    • T.A. Barr, P. Shen, S. Brown, V. Lampropoulou, T. Roch, S. Lawrie, and et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells J. Exp. Med. 209 2012 1001 1010
    • (2012) J. Exp. Med. , vol.209 , pp. 1001-1010
    • Barr, T.A.1    Shen, P.2    Brown, S.3    Lampropoulou, V.4    Roch, T.5    Lawrie, S.6
  • 25
    • 79952762854 scopus 로고    scopus 로고
    • Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica
    • N. Chihara, T. Aranami, W. Sato, Y. Miyazaki, S. Miyake, T. Okamoto, and et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica Proc. Natl. Acad. Sci. U. S. A. 108 2011 3701 3706
    • (2011) Proc. Natl. Acad. Sci. U. S. A. , vol.108 , pp. 3701-3706
    • Chihara, N.1    Aranami, T.2    Sato, W.3    Miyazaki, Y.4    Miyake, S.5    Okamoto, T.6
  • 26
    • 84924588068 scopus 로고    scopus 로고
    • Cutting edge: Circulating plasmablasts induce the differentiation of human T follicular helper cells via IL-6 production
    • K.M. Chavele, E. Merry, and M.R. Ehrenstein Cutting edge: circulating plasmablasts induce the differentiation of human T follicular helper cells via IL-6 production J. Immunol. 194 2015 2482 2485
    • (2015) J. Immunol. , vol.194 , pp. 2482-2485
    • Chavele, K.M.1    Merry, E.2    Ehrenstein, M.R.3
  • 28
    • 84895519112 scopus 로고    scopus 로고
    • Protein kinase C isoforms in atherosclerosis: Pro- or anti-inflammatory?
    • H.C. Fan, C. Fernandez-Hernando, and J.H. Lai Protein kinase C isoforms in atherosclerosis: pro- or anti-inflammatory? Biochem. Pharmacol. 88 2014 139 149
    • (2014) Biochem. Pharmacol. , vol.88 , pp. 139-149
    • Fan, H.C.1    Fernandez-Hernando, C.2    Lai, J.H.3
  • 29
    • 43249118045 scopus 로고    scopus 로고
    • Long-term interleukin-6 levels and subsequent risk of coronary heart disease: Two new prospective studies and a systematic review
    • J. Danesh, S. Kaptoge, A.G. Mann, N. Sarwar, A. Wood, S.B. Angleman, and et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review PLoS Med. 5 2008 e78
    • (2008) PLoS Med. , vol.5 , pp. e78
    • Danesh, J.1    Kaptoge, S.2    Mann, A.G.3    Sarwar, N.4    Wood, A.5    Angleman, S.B.6
  • 30
    • 0037458105 scopus 로고    scopus 로고
    • Interleukin-6-deficient mice resist development of autoimmune myocarditis associated with impaired upregulation of complement C3
    • U. Eriksson, M.O. Kurrer, N. Schmitz, S.C. Marsch, A. Fontana, H.P. Eugster, and et al. Interleukin-6-deficient mice resist development of autoimmune myocarditis associated with impaired upregulation of complement C3 Circulation 107 2003 320 325
    • (2003) Circulation , vol.107 , pp. 320-325
    • Eriksson, U.1    Kurrer, M.O.2    Schmitz, N.3    Marsch, S.C.4    Fontana, A.5    Eugster, H.P.6
  • 31
    • 84860524460 scopus 로고    scopus 로고
    • Macrophage-stimulated cardiac fibroblast production of IL-6 is essential for TGF beta/Smad activation and cardiac fibrosis induced by angiotensin II
    • F. Ma, Y. Li, L. Jia, Y. Han, J. Cheng, H. Li, and et al. Macrophage-stimulated cardiac fibroblast production of IL-6 is essential for TGF beta/Smad activation and cardiac fibrosis induced by angiotensin II PLOS ONE 7 2012 e35144
    • (2012) PLOS ONE , vol.7 , pp. e35144
    • Ma, F.1    Li, Y.2    Jia, L.3    Han, Y.4    Cheng, J.5    Li, H.6
  • 32
    • 84930177360 scopus 로고    scopus 로고
    • The varying faces of IL-6: From cardiac protection to cardiac failure
    • J.A. Fontes, N.R. Rose, and D. Cihakova The varying faces of IL-6: from cardiac protection to cardiac failure Cytokine 2015 10.1016/j.cyto.2014.12.024
    • (2015) Cytokine
    • Fontes, J.A.1    Rose, N.R.2    Cihakova, D.3
  • 33
    • 69949138556 scopus 로고    scopus 로고
    • IL-6 during viral-induced chronic autoimmune myocarditis
    • M.C. Poffenberger, and M.S. Horwitz IL-6 during viral-induced chronic autoimmune myocarditis Ann. N. Y. Acad. Sci. 1173 2009 318 325
    • (2009) Ann. N. Y. Acad. Sci. , vol.1173 , pp. 318-325
    • Poffenberger, M.C.1    Horwitz, M.S.2
  • 34
    • 84869834766 scopus 로고    scopus 로고
    • Role of IL-6 in asthma and other inflammatory pulmonary diseases
    • M. Rincon, and C.G. Irvin Role of IL-6 in asthma and other inflammatory pulmonary diseases Int. J. Biol. Sci. 8 2012 1281 1290
    • (2012) Int. J. Biol. Sci. , vol.8 , pp. 1281-1290
    • Rincon, M.1    Irvin, C.G.2
  • 35
    • 84896317905 scopus 로고    scopus 로고
    • IL-6/Stat3-driven pulmonary inflammation, but not emphysema, is dependent on interleukin-17A in mice
    • S.M. Ruwanpura, L. McLeod, G.D. Brooks, S. Bozinovski, R. Vlahos, A. Longano, and et al. IL-6/Stat3-driven pulmonary inflammation, but not emphysema, is dependent on interleukin-17A in mice Respirology 19 2014 419 427
    • (2014) Respirology , vol.19 , pp. 419-427
    • Ruwanpura, S.M.1    McLeod, L.2    Brooks, G.D.3    Bozinovski, S.4    Vlahos, R.5    Longano, A.6
  • 37
    • 84874606609 scopus 로고    scopus 로고
    • IL-6 trans-signaling promotes pancreatitis-associated lung injury and lethality
    • H. Zhang, P. Neuhofer, L. Song, B. Rabe, M. Lesina, M.U. Kurkowski, and et al. IL-6 trans-signaling promotes pancreatitis-associated lung injury and lethality J. Clin. Invest. 123 2013 1019 1031
    • (2013) J. Clin. Invest. , vol.123 , pp. 1019-1031
    • Zhang, H.1    Neuhofer, P.2    Song, L.3    Rabe, B.4    Lesina, M.5    Kurkowski, M.U.6
  • 38
    • 84927511163 scopus 로고    scopus 로고
    • Lung parenchyma-derived IL-6 promotes IL-17A-dependent acute lung injury after allogeneic stem cell transplantation
    • A. Varelias, K.H. Gartlan, E. Kreijveld, S.D. Olver, M. Lor, R.D. Kuns, and et al. Lung parenchyma-derived IL-6 promotes IL-17A-dependent acute lung injury after allogeneic stem cell transplantation Blood 125 2015 2435 2444
    • (2015) Blood , vol.125 , pp. 2435-2444
    • Varelias, A.1    Gartlan, K.H.2    Kreijveld, E.3    Olver, S.D.4    Lor, M.5    Kuns, R.D.6
  • 39
    • 16844387413 scopus 로고    scopus 로고
    • The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury
    • C. Klein, T. Wustefeld, U. Assmus, T. Roskams, S. Rose-John, M. Muller, and et al. The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury J. Clin. Invest. 115 2005 860 869
    • (2005) J. Clin. Invest. , vol.115 , pp. 860-869
    • Klein, C.1    Wustefeld, T.2    Assmus, U.3    Roskams, T.4    Rose-John, S.5    Muller, M.6
  • 40
    • 84899767448 scopus 로고    scopus 로고
    • Synthesis of IL-6 by hepatocytes is a normal response to common hepatic stimuli
    • C.A. Norris, M. He, L.I. Kang, M.Q. Ding, J.E. Radder, M.M. Haynes, and et al. Synthesis of IL-6 by hepatocytes is a normal response to common hepatic stimuli PLOS ONE 9 2014 e96053
    • (2014) PLOS ONE , vol.9 , pp. e96053
    • Norris, C.A.1    He, M.2    Kang, L.I.3    Ding, M.Q.4    Radder, J.E.5    Haynes, M.M.6
  • 41
    • 84864398664 scopus 로고    scopus 로고
    • DEC1 binding to the proximal promoter of CYP3A4 ascribes to the downregulation of CYP3A4 expression by IL-6 in primary human hepatocytes
    • Z. Mao, X. Luan, G. Cao, W. Liu, J. Xiong, G. Hu, and et al. DEC1 binding to the proximal promoter of CYP3A4 ascribes to the downregulation of CYP3A4 expression by IL-6 in primary human hepatocytes Biochem. Pharmacol. 84 2012 701 711
    • (2012) Biochem. Pharmacol. , vol.84 , pp. 701-711
    • Mao, Z.1    Luan, X.2    Cao, G.3    Liu, W.4    Xiong, J.5    Hu, G.6
  • 42
    • 0029934454 scopus 로고    scopus 로고
    • IL-6-deficient mice exhibit normal mucosal IgA responses to local immunizations and Helicobacter felis infection
    • A.K. Bromander, L. Ekman, M. Kopf, J.G. Nedrud, and N.Y. Lycke IL-6-deficient mice exhibit normal mucosal IgA responses to local immunizations and Helicobacter felis infection J. Immunol. 156 1996 4290 4297
    • (1996) J. Immunol. , vol.156 , pp. 4290-4297
    • Bromander, A.K.1    Ekman, L.2    Kopf, M.3    Nedrud, J.G.4    Lycke, N.Y.5
  • 43
    • 77149155643 scopus 로고    scopus 로고
    • Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis
    • Y. Li, C. de Haar, M. Chen, J. Deuring, M.M. Gerrits, R. Smits, and et al. Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis Gut 59 2010 227 235
    • (2010) Gut , vol.59 , pp. 227-235
    • Li, Y.1    De Haar, C.2    Chen, M.3    Deuring, J.4    Gerrits, M.M.5    Smits, R.6
  • 44
    • 18344410191 scopus 로고    scopus 로고
    • Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo
    • R. Atreya, J. Mudter, S. Finotto, J. Mullberg, T. Jostock, S. Wirtz, and et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo Nat. Med. 6 2000 583 588
    • (2000) Nat. Med. , vol.6 , pp. 583-588
    • Atreya, R.1    Mudter, J.2    Finotto, S.3    Mullberg, J.4    Jostock, T.5    Wirtz, S.6
  • 45
    • 84918522920 scopus 로고    scopus 로고
    • IL-6 stimulates intestinal epithelial proliferation and repair after injury
    • K.A. Kuhn, N.A. Manieri, T.C. Liu, and T.S. Stappenbeck IL-6 stimulates intestinal epithelial proliferation and repair after injury PLOS ONE 9 2014 e114195
    • (2014) PLOS ONE , vol.9 , pp. e114195
    • Kuhn, K.A.1    Manieri, N.A.2    Liu, T.C.3    Stappenbeck, T.S.4
  • 46
    • 73649123508 scopus 로고    scopus 로고
    • Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: The IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus
    • H. Cash, M. Relle, J. Menke, C. Brochhausen, S.A. Jones, N. Topley, and et al. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus J. Rheumatol. 37 2010 60 70
    • (2010) J. Rheumatol. , vol.37 , pp. 60-70
    • Cash, H.1    Relle, M.2    Menke, J.3    Brochhausen, C.4    Jones, S.A.5    Topley, N.6
  • 47
    • 84885126530 scopus 로고    scopus 로고
    • Interleukin-6 trans-signaling exacerbates inflammation and renal pathology in lupus-prone mice
    • E. Tsantikos, M.J. Maxwell, T. Putoczki, M. Ernst, S. Rose-John, D.M. Tarlinton, and et al. Interleukin-6 trans-signaling exacerbates inflammation and renal pathology in lupus-prone mice Arthritis Rheum. 65 2013 2691 2702
    • (2013) Arthritis Rheum. , vol.65 , pp. 2691-2702
    • Tsantikos, E.1    Maxwell, M.J.2    Putoczki, T.3    Ernst, M.4    Rose-John, S.5    Tarlinton, D.M.6
  • 48
    • 84924580495 scopus 로고    scopus 로고
    • Inflammation-induced IL-6 functions as a natural brake on macrophages and limits GN
    • M. Luig, M.A. Kluger, B. Goerke, M. Meyer, A. Nosko, I. Yan, and et al. Inflammation-induced IL-6 functions as a natural brake on macrophages and limits GN J. Am. Soc. Nephrol. 2015 10.1681/ASN.2014060620
    • (2015) J. Am. Soc. Nephrol.
    • Luig, M.1    Kluger, M.A.2    Goerke, B.3    Meyer, M.4    Nosko, A.5    Yan, I.6
  • 49
    • 84904558110 scopus 로고    scopus 로고
    • IL-6 in diabetes and cardiovascular complications
    • D. Qu, J. Liu, C.W. Lau, and Y. Huang IL-6 in diabetes and cardiovascular complications Br. J. Pharmacol. 171 2014 3595 3603
    • (2014) Br. J. Pharmacol. , vol.171 , pp. 3595-3603
    • Qu, D.1    Liu, J.2    Lau, C.W.3    Huang, Y.4
  • 50
    • 84908161000 scopus 로고    scopus 로고
    • Revisiting STAT3 signalling in cancer: New and unexpected biological functions
    • H. Yu, H. Lee, A. Herrmann, R. Buettner, and R. Jove Revisiting STAT3 signalling in cancer: new and unexpected biological functions Nat. Rev. Cancer 14 2014 736 746
    • (2014) Nat. Rev. Cancer , vol.14 , pp. 736-746
    • Yu, H.1    Lee, H.2    Herrmann, A.3    Buettner, R.4    Jove, R.5
  • 51
    • 0028805674 scopus 로고
    • Enhancement of transformation in vitro of a nontumorigenic rat urothelial cell line by interleukin 6
    • M. Okamoto, H. Kawamata, K. Kawai, and R. Oyasu Enhancement of transformation in vitro of a nontumorigenic rat urothelial cell line by interleukin 6 Cancer Res. 55 1995 4581 4585
    • (1995) Cancer Res. , vol.55 , pp. 4581-4585
    • Okamoto, M.1    Kawamata, H.2    Kawai, K.3    Oyasu, R.4
  • 52
    • 36849039660 scopus 로고    scopus 로고
    • IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland
    • P. Sansone, G. Storci, S. Tavolari, T. Guarnieri, C. Giovannini, M. Taffurelli, and et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland J. Clin. Invest. 117 2007 3988 4002
    • (2007) J. Clin. Invest. , vol.117 , pp. 3988-4002
    • Sansone, P.1    Storci, G.2    Tavolari, S.3    Guarnieri, T.4    Giovannini, C.5    Taffurelli, M.6
  • 53
    • 84877040826 scopus 로고    scopus 로고
    • Enhanced IL-6/IL-6R signaling promotes growth and malignant properties in EBV-infected premalignant and cancerous nasopharyngeal epithelial cells
    • G. Zhang, C.M. Tsang, W. Deng, Y.L. Yip, V.W. Lui, S.C. Wong, and et al. Enhanced IL-6/IL-6R signaling promotes growth and malignant properties in EBV-infected premalignant and cancerous nasopharyngeal epithelial cells PLOS ONE 8 2013 e62284
    • (2013) PLOS ONE , vol.8 , pp. e62284
    • Zhang, G.1    Tsang, C.M.2    Deng, W.3    Yip, Y.L.4    Lui, V.W.5    Wong, S.C.6
  • 54
    • 58649108302 scopus 로고    scopus 로고
    • IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer
    • S. Grivennikov, E. Karin, J. Terzic, D. Mucida, G.Y. Yu, S. Vallabhapurapu, and et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer Cancer Cell 15 2009 103 113
    • (2009) Cancer Cell , vol.15 , pp. 103-113
    • Grivennikov, S.1    Karin, E.2    Terzic, J.3    Mucida, D.4    Yu, G.Y.5    Vallabhapurapu, S.6
  • 55
    • 84882714320 scopus 로고    scopus 로고
    • JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells
    • P. Kroon, P.A. Berry, M.J. Stower, G. Rodrigues, V.M. Mann, M. Simms, and et al. JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells Cancer Res. 73 2013 5288 5298
    • (2013) Cancer Res. , vol.73 , pp. 5288-5298
    • Kroon, P.1    Berry, P.A.2    Stower, M.J.3    Rodrigues, G.4    Mann, V.M.5    Simms, M.6
  • 56
    • 84939572294 scopus 로고    scopus 로고
    • Biomechanical and biochemical remodeling of stromal extracellular matrix in cancer
    • R. Malik, P.I. Lelkes, and E. Cukierman Biomechanical and biochemical remodeling of stromal extracellular matrix in cancer Trends Biotechnol. 33 2015 230 236
    • (2015) Trends Biotechnol. , vol.33 , pp. 230-236
    • Malik, R.1    Lelkes, P.I.2    Cukierman, E.3
  • 57
    • 84938199098 scopus 로고    scopus 로고
    • IL-6 originated from breast cancer tissue-derived mesenchymal stromal cells may contribute to carcinogenesis
    • O. Saglam, Z.S. Unal, C. Subasi, E. Ulukaya, and E. Karaoz IL-6 originated from breast cancer tissue-derived mesenchymal stromal cells may contribute to carcinogenesis Tumour Biol. 2015 10.1007/s13277-015-3241-5
    • (2015) Tumour Biol.
    • Saglam, O.1    Unal, Z.S.2    Subasi, C.3    Ulukaya, E.4    Karaoz, E.5
  • 58
    • 84892917277 scopus 로고    scopus 로고
    • Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: Anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction
    • T. Nagasaki, M. Hara, H. Nakanishi, H. Takahashi, M. Sato, and H. Takeyama Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction Br. J. Cancer 110 2014 469 478
    • (2014) Br. J. Cancer , vol.110 , pp. 469-478
    • Nagasaki, T.1    Hara, M.2    Nakanishi, H.3    Takahashi, H.4    Sato, M.5    Takeyama, H.6
  • 59
    • 84920653683 scopus 로고    scopus 로고
    • The tumor microenvironment is the main source of IL-6 for plasma cell tumor development in mice
    • T.R. Rosean, V.S. Tompkins, A.K. Olivier, R. Sompallae, L.A. Norian, H.C. Morse 3rd, and et al. The tumor microenvironment is the main source of IL-6 for plasma cell tumor development in mice Leukemia 29 2015 233 237
    • (2015) Leukemia , vol.29 , pp. 233-237
    • Rosean, T.R.1    Tompkins, V.S.2    Olivier, A.K.3    Sompallae, R.4    Norian, L.A.5    Morse, H.C.6
  • 60
    • 84909607972 scopus 로고    scopus 로고
    • The cytokine IL-6 reactivates breast stromal fibroblasts through transcription factor STAT3-dependent up-regulation of the RNA-binding protein AUF1
    • S.F. Hendrayani, H.H. Al-Khalaf, and A. Aboussekhra The cytokine IL-6 reactivates breast stromal fibroblasts through transcription factor STAT3-dependent up-regulation of the RNA-binding protein AUF1 J. Biol. Chem. 289 2014 30962 30976
    • (2014) J. Biol. Chem. , vol.289 , pp. 30962-30976
    • Hendrayani, S.F.1    Al-Khalaf, H.H.2    Aboussekhra, A.3
  • 61
    • 84900035813 scopus 로고    scopus 로고
    • Activation of a positive feedback loop involving IL-6 and aromatase promotes intratumoral 17beta-estradiol biosynthesis in endometrial carcinoma microenvironment
    • Q. Che, B.Y. Liu, Y. Liao, H.J. Zhang, T.T. Yang, Y.Y. He, and et al. Activation of a positive feedback loop involving IL-6 and aromatase promotes intratumoral 17beta-estradiol biosynthesis in endometrial carcinoma microenvironment Int. J. Cancer 135 2014 282 294
    • (2014) Int. J. Cancer , vol.135 , pp. 282-294
    • Che, Q.1    Liu, B.Y.2    Liao, Y.3    Zhang, H.J.4    Yang, T.T.5    He, Y.Y.6
  • 62
    • 84894593599 scopus 로고    scopus 로고
    • Molecular mechanisms of epithelial-mesenchymal transition
    • S. Lamouille, J. Xu, and R. Derynck Molecular mechanisms of epithelial-mesenchymal transition Nat. Rev. Mol. Cell Biol. 15 2014 178 196
    • (2014) Nat. Rev. Mol. Cell Biol. , vol.15 , pp. 178-196
    • Lamouille, S.1    Xu, J.2    Derynck, R.3
  • 63
    • 69249221254 scopus 로고    scopus 로고
    • Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells
    • N.J. Sullivan, A.K. Sasser, A.E. Axel, F. Vesuna, V. Raman, N. Ramirez, and et al. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells Oncogene 28 2009 2940 2947
    • (2009) Oncogene , vol.28 , pp. 2940-2947
    • Sullivan, N.J.1    Sasser, A.K.2    Axel, A.E.3    Vesuna, F.4    Raman, V.5    Ramirez, N.6
  • 64
    • 84055207487 scopus 로고    scopus 로고
    • IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway
    • A. Yadav, B. Kumar, J. Datta, T.N. Teknos, and P. Kumar IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway Mol. Cancer Res. 9 2011 1658 1667
    • (2011) Mol. Cancer Res. , vol.9 , pp. 1658-1667
    • Yadav, A.1    Kumar, B.2    Datta, J.3    Teknos, T.N.4    Kumar, P.5
  • 65
    • 84899114827 scopus 로고    scopus 로고
    • Widespread FRA1-dependent control of mesenchymal transdifferentiation programs in colorectal cancer cells
    • J. Diesch, E. Sanij, O. Gilan, C. Love, H. Tran, N.I. Fleming, and et al. Widespread FRA1-dependent control of mesenchymal transdifferentiation programs in colorectal cancer cells PLOS ONE 9 2014 e88950
    • (2014) PLOS ONE , vol.9 , pp. e88950
    • Diesch, J.1    Sanij, E.2    Gilan, O.3    Love, C.4    Tran, H.5    Fleming, N.I.6
  • 66
    • 84927628854 scopus 로고    scopus 로고
    • Aberrantly expressed Fra-1 by IL-6/STAT3 transactivation promotes colorectal cancer aggressiveness through epithelial-mesenchymal transition
    • H. Liu, G. Ren, T. Wang, Y. Chen, C. Gong, Y. Bai, and et al. Aberrantly expressed Fra-1 by IL-6/STAT3 transactivation promotes colorectal cancer aggressiveness through epithelial-mesenchymal transition Carcinogenesis 36 2015 459 468
    • (2015) Carcinogenesis , vol.36 , pp. 459-468
    • Liu, H.1    Ren, G.2    Wang, T.3    Chen, Y.4    Gong, C.5    Bai, Y.6
  • 67
    • 0030046481 scopus 로고    scopus 로고
    • Interleukin 6 induces the expression of vascular endothelial growth factor
    • T. Cohen, D. Nahari, L.W. Cerem, G. Neufeld, and B.Z. Levi Interleukin 6 induces the expression of vascular endothelial growth factor J. Biol. Chem. 271 1996 736 741
    • (1996) J. Biol. Chem. , vol.271 , pp. 736-741
    • Cohen, T.1    Nahari, D.2    Cerem, L.W.3    Neufeld, G.4    Levi, B.Z.5
  • 68
    • 79953183679 scopus 로고    scopus 로고
    • IL-6 increases MMP-13 expression and motility in human chondrosarcoma cells
    • C.H. Tang, C.F. Chen, W.M. Chen, and Y.C. Fong IL-6 increases MMP-13 expression and motility in human chondrosarcoma cells J. Biol. Chem. 286 2011 11056 11066
    • (2011) J. Biol. Chem. , vol.286 , pp. 11056-11066
    • Tang, C.H.1    Chen, C.F.2    Chen, W.M.3    Fong, Y.C.4
  • 69
    • 79954570471 scopus 로고    scopus 로고
    • IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer
    • M.S. Anglesio, J. George, H. Kulbe, M. Friedlander, D. Rischin, C. Lemech, and et al. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer Clin. Cancer Res. 17 2011 2538 2548
    • (2011) Clin. Cancer Res. , vol.17 , pp. 2538-2548
    • Anglesio, M.S.1    George, J.2    Kulbe, H.3    Friedlander, M.4    Rischin, D.5    Lemech, C.6
  • 70
    • 84872681084 scopus 로고    scopus 로고
    • Interleukin-6 induces vascular endothelial growth factor expression and promotes angiogenesis through apoptosis signal-regulating kinase 1 in human osteosarcoma
    • H.E. Tzeng, C.H. Tsai, Z.L. Chang, C.M. Su, S.W. Wang, W.L. Hwang, and et al. Interleukin-6 induces vascular endothelial growth factor expression and promotes angiogenesis through apoptosis signal-regulating kinase 1 in human osteosarcoma Biochem. Pharmacol. 85 2013 531 540
    • (2013) Biochem. Pharmacol. , vol.85 , pp. 531-540
    • Tzeng, H.E.1    Tsai, C.H.2    Chang, Z.L.3    Su, C.M.4    Wang, S.W.5    Hwang, W.L.6
  • 71
    • 33749336430 scopus 로고    scopus 로고
    • Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity
    • J. Domingo-Domenech, C. Oliva, A. Rovira, J. Codony-Servat, M. Bosch, X. Filella, and et al. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity Clin. Cancer Res. 12 2006 5578 5586
    • (2006) Clin. Cancer Res. , vol.12 , pp. 5578-5586
    • Domingo-Domenech, J.1    Oliva, C.2    Rovira, A.3    Codony-Servat, J.4    Bosch, M.5    Filella, X.6
  • 72
    • 84909987265 scopus 로고    scopus 로고
    • Interleukin 6 augments lung cancer chemotherapeutic resistance via ataxia-telangiectasia mutated/NF-kappaB pathway activation
    • H.Q. Yan, X.B. Huang, S.Z. Ke, Y.N. Jiang, Y.H. Zhang, Y.N. Wang, and et al. Interleukin 6 augments lung cancer chemotherapeutic resistance via ataxia-telangiectasia mutated/NF-kappaB pathway activation Cancer Sci. 105 2014 1220 1227
    • (2014) Cancer Sci. , vol.105 , pp. 1220-1227
    • Yan, H.Q.1    Huang, X.B.2    Ke, S.Z.3    Jiang, Y.N.4    Zhang, Y.H.5    Wang, Y.N.6
  • 73
    • 84888393766 scopus 로고    scopus 로고
    • Autocrine production of interleukin-6 confers ovarian cancer cells resistance to tamoxifen via ER isoforms and SRC-1
    • Y. Wang, Y. Qu, X.L. Zhang, J. Xing, X.L. Niu, X. Chen, and et al. Autocrine production of interleukin-6 confers ovarian cancer cells resistance to tamoxifen via ER isoforms and SRC-1 Mol. Cell. Endocrinol. 382 2014 791 803
    • (2014) Mol. Cell. Endocrinol. , vol.382 , pp. 791-803
    • Wang, Y.1    Qu, Y.2    Zhang, X.L.3    Xing, J.4    Niu, X.L.5    Chen, X.6
  • 74
    • 84906814857 scopus 로고    scopus 로고
    • IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer
    • X. Sun, Y. Mao, J. Wang, L. Zu, M. Hao, G. Cheng, and et al. IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer Oncogene 2014 10.1038/onc.2014.158
    • (2014) Oncogene
    • Sun, X.1    Mao, Y.2    Wang, J.3    Zu, L.4    Hao, M.5    Cheng, G.6
  • 75
    • 0024459013 scopus 로고
    • Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease
    • K. Yoshizaki, T. Matsuda, N. Nishimoto, T. Kuritani, L. Taeho, K. Aozasa, and et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease Blood 74 1989 1360 1367
    • (1989) Blood , vol.74 , pp. 1360-1367
    • Yoshizaki, K.1    Matsuda, T.2    Nishimoto, N.3    Kuritani, T.4    Taeho, L.5    Aozasa, K.6
  • 76
    • 0033959608 scopus 로고    scopus 로고
    • Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy
    • N. Nishimoto, M. Sasai, Y. Shima, M. Nakagawa, T. Matsumoto, T. Shirai, and et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy Blood 95 2000 56 61
    • (2000) Blood , vol.95 , pp. 56-61
    • Nishimoto, N.1    Sasai, M.2    Shima, Y.3    Nakagawa, M.4    Matsumoto, T.5    Shirai, T.6
  • 77
    • 1942485431 scopus 로고    scopus 로고
    • Chinese herbs as immunomodulators and potential disease-modifying antirheumatic drugs in autoimmune disorders
    • L.J. Ho, and J.H. Lai Chinese herbs as immunomodulators and potential disease-modifying antirheumatic drugs in autoimmune disorders Curr. Drug Metab. 5 2004 181 192
    • (2004) Curr. Drug Metab. , vol.5 , pp. 181-192
    • Ho, L.J.1    Lai, J.H.2
  • 78
    • 0029060421 scopus 로고
    • Interleukin-6 (IL-6) induces the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 receptor
    • M. Mihara, Y. Moriya, T. Kishimoto, and Y. Ohsugi Interleukin-6 (IL-6) induces the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 receptor Br. J. Rheumatol. 34 1995 321 325
    • (1995) Br. J. Rheumatol. , vol.34 , pp. 321-325
    • Mihara, M.1    Moriya, Y.2    Kishimoto, T.3    Ohsugi, Y.4
  • 79
    • 84921465148 scopus 로고    scopus 로고
    • Small-molecule inhibitors for autoimmune arthritis: Success, failure and the future
    • L.J. Ho, and J.H. Lai Small-molecule inhibitors for autoimmune arthritis: success, failure and the future Eur. J. Pharmacol. 747 2015 200 205
    • (2015) Eur. J. Pharmacol. , vol.747 , pp. 200-205
    • Ho, L.J.1    Lai, J.H.2
  • 80
    • 84929023302 scopus 로고    scopus 로고
    • Rheumatoid arthritis therapy reappraisal: Strategies, opportunities and challenges
    • J.S. Smolen, and D. Aletaha Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges Nat. Rev. Rheumatol. 2015 10.1038/nrrheum.2015.8
    • (2015) Nat. Rev. Rheumatol.
    • Smolen, J.S.1    Aletaha, D.2
  • 81
    • 2642558925 scopus 로고    scopus 로고
    • Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: A multicenter, double-blind, placebo-controlled trial
    • N. Nishimoto, K. Yoshizaki, N. Miyasaka, K. Yamamoto, S. Kawai, T. Takeuchi, and et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial Arthritis Rheum. 50 2004 1761 1769
    • (2004) Arthritis Rheum. , vol.50 , pp. 1761-1769
    • Nishimoto, N.1    Yoshizaki, K.2    Miyasaka, N.3    Yamamoto, K.4    Kawai, S.5    Takeuchi, T.6
  • 82
    • 34447300492 scopus 로고    scopus 로고
    • Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an X ray reader-blinded randomised controlled trial of tocilizumab
    • N. Nishimoto, J. Hashimoto, N. Miyasaka, K. Yamamoto, S. Kawai, T. Takeuchi, and et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X ray reader-blinded randomised controlled trial of tocilizumab Ann. Rheum. Dis. 66 2007 1162 1167
    • (2007) Ann. Rheum. Dis. , vol.66 , pp. 1162-1167
    • Nishimoto, N.1    Hashimoto, J.2    Miyasaka, N.3    Yamamoto, K.4    Kawai, S.5    Takeuchi, T.6
  • 83
    • 84871093047 scopus 로고    scopus 로고
    • Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)
    • M. Dougados, K. Kissel, T. Sheeran, P.P. Tak, P.G. Conaghan, E.M. Mola, and et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY) Ann. Rheum. Dis. 72 2013 43 50
    • (2013) Ann. Rheum. Dis. , vol.72 , pp. 43-50
    • Dougados, M.1    Kissel, K.2    Sheeran, T.3    Tak, P.P.4    Conaghan, P.G.5    Mola, E.M.6
  • 84
    • 84923550944 scopus 로고    scopus 로고
    • Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: Results from a phase III trial
    • F. De Benedetti, H. Brunner, N. Ruperto, R. Schneider, R. Xavier, R. Allen, and et al. Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: results from a phase III trial Arthritis Rheumatol. 67 2015 840 848
    • (2015) Arthritis Rheumatol. , vol.67 , pp. 840-848
    • De Benedetti, F.1    Brunner, H.2    Ruperto, N.3    Schneider, R.4    Xavier, R.5    Allen, R.6
  • 85
    • 84901594789 scopus 로고    scopus 로고
    • Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still's disease: Multicenter retrospective open-label study of thirty-four patients
    • F. Ortiz-Sanjuan, R. Blanco, V. Calvo-Rio, J. Narvaez, E. Rubio Romero, A. Olive, and et al. Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still's disease: multicenter retrospective open-label study of thirty-four patients Arthritis Rheumatol. 66 2014 1659 1665
    • (2014) Arthritis Rheumatol. , vol.66 , pp. 1659-1665
    • Ortiz-Sanjuan, F.1    Blanco, R.2    Calvo-Rio, V.3    Narvaez, J.4    Rubio Romero, E.5    Olive, A.6
  • 88
    • 84899708467 scopus 로고    scopus 로고
    • Discovery and characterization of olokizumab: A humanized antibody targeting interleukin-6 and neutralizing gp130-signaling
    • S. Shaw, T. Bourne, C. Meier, B. Carrington, R. Gelinas, A. Henry, and et al. Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling mAbs 6 2014 774 782
    • (2014) MAbs , vol.6 , pp. 774-782
    • Shaw, S.1    Bourne, T.2    Meier, C.3    Carrington, B.4    Gelinas, R.5    Henry, A.6
  • 89
    • 84905164026 scopus 로고    scopus 로고
    • Sirukumab, a human anti-interleukin-6 monoclonal antibody: A randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy
    • J.S. Smolen, M.E. Weinblatt, S. Sheng, Y. Zhuang, and B. Hsu Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy Ann. Rheum. Dis. 73 2014 1616 1625
    • (2014) Ann. Rheum. Dis. , vol.73 , pp. 1616-1625
    • Smolen, J.S.1    Weinblatt, M.E.2    Sheng, S.3    Zhuang, Y.4    Hsu, B.5
  • 90
    • 83255176682 scopus 로고    scopus 로고
    • Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer
    • K. Fizazi, J.S. De Bono, A. Flechon, A. Heidenreich, E. Voog, N.B. Davis, and et al. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer Eur. J. Cancer 48 2012 85 93
    • (2012) Eur. J. Cancer , vol.48 , pp. 85-93
    • Fizazi, K.1    De Bono, J.S.2    Flechon, A.3    Heidenreich, A.4    Voog, E.5    Davis, N.B.6
  • 91
    • 84862783578 scopus 로고    scopus 로고
    • A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate
    • P. Mease, V. Strand, L. Shalamberidze, A. Dimic, T. Raskina, L.A. Xu, and et al. A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate Ann. Rheum. Dis. 71 2012 1183 1189
    • (2012) Ann. Rheum. Dis. , vol.71 , pp. 1183-1189
    • Mease, P.1    Strand, V.2    Shalamberidze, L.3    Dimic, A.4    Raskina, T.5    Xu, L.A.6
  • 92
    • 84905179575 scopus 로고    scopus 로고
    • Sarilumab, a fully human monoclonal antibody against IL-6Ralpha in patients with rheumatoid arthritis and an inadequate response to methotrexate: Efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial
    • T.W. Huizinga, R.M. Fleischmann, M. Jasson, A.R. Radin, J. van Adelsberg, S. Fiore, and et al. Sarilumab, a fully human monoclonal antibody against IL-6Ralpha in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial Ann. Rheum. Dis. 73 2014 1626 1634
    • (2014) Ann. Rheum. Dis. , vol.73 , pp. 1626-1634
    • Huizinga, T.W.1    Fleischmann, R.M.2    Jasson, M.3    Radin, A.R.4    Van Adelsberg, J.5    Fiore, S.6
  • 93
    • 70450238013 scopus 로고    scopus 로고
    • Inhibition of interleukin-6-transsignaling via gp130-Fc in hemorrhagic shock and sepsis
    • S.T. Mees, S. Toellner, K. Marx, F. Faendrich, K.J. Kallen, J. Schroeder, and et al. Inhibition of interleukin-6-transsignaling via gp130-Fc in hemorrhagic shock and sepsis J. Surg. Res. 157 2009 235 242
    • (2009) J. Surg. Res. , vol.157 , pp. 235-242
    • Mees, S.T.1    Toellner, S.2    Marx, K.3    Faendrich, F.4    Kallen, K.J.5    Schroeder, J.6
  • 94
    • 84905192115 scopus 로고    scopus 로고
    • Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: Outcomes of a randomised phase IIb study
    • M.C. Genovese, R. Fleischmann, D. Furst, N. Janssen, J. Carter, B. Dasgupta, and et al. Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised phase IIb study Ann. Rheum. Dis. 73 2014 1607 1615
    • (2014) Ann. Rheum. Dis. , vol.73 , pp. 1607-1615
    • Genovese, M.C.1    Fleischmann, R.2    Furst, D.3    Janssen, N.4    Carter, J.5    Dasgupta, B.6
  • 95
    • 84929881847 scopus 로고    scopus 로고
    • Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: Results of a phase III study
    • M.C. Genovese, R. Fleischmann, A. Kivitz, M. Rell-Bakalarska, R. Martincova, S. Fiore, and et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study Arthritis Rheumatol. 2015 10.1002/art.39093
    • (2015) Arthritis Rheumatol.
    • Genovese, M.C.1    Fleischmann, R.2    Kivitz, A.3    Rell-Bakalarska, M.4    Martincova, R.5    Fiore, S.6
  • 96
    • 84931575213 scopus 로고    scopus 로고
    • Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models of pancreatic cancer
    • F.A. Goumas, R. Holmer, J.H. Egberts, A. Gontarewicz, C. Heneweer, U. Geisen, and et al. Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models of pancreatic cancer Int. J. Cancer 2015 10.1002/ijc.29445
    • (2015) Int. J. Cancer
    • Goumas, F.A.1    Holmer, R.2    Egberts, J.H.3    Gontarewicz, A.4    Heneweer, C.5    Geisen, U.6
  • 97
    • 84898967209 scopus 로고    scopus 로고
    • A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors
    • E. Angevin, J. Tabernero, E. Elez, S.J. Cohen, R. Bahleda, J.L. van Laethem, and et al. A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors Clin. Cancer Res. 20 2014 2192 2204
    • (2014) Clin. Cancer Res. , vol.20 , pp. 2192-2204
    • Angevin, E.1    Tabernero, J.2    Elez, E.3    Cohen, S.J.4    Bahleda, R.5    Van Laethem, J.L.6
  • 98
    • 77957995258 scopus 로고    scopus 로고
    • A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer
    • J.F. Rossi, S. Negrier, N.D. James, I. Kocak, R. Hawkins, H. Davis, and et al. A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer Br. J. Cancer 103 2010 1154 1162
    • (2010) Br. J. Cancer , vol.103 , pp. 1154-1162
    • Rossi, J.F.1    Negrier, S.2    James, N.D.3    Kocak, I.4    Hawkins, R.5    Davis, H.6
  • 99
    • 77953091816 scopus 로고    scopus 로고
    • Clinical and correlative results of SWOG S0354: A phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer
    • T.B. Dorff, B. Goldman, J.K. Pinski, P.C. Mack, P.N. Lara Jr., P.J. Van Veldhuizen Jr., and et al. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer Clin. Cancer Res. 16 2010 3028 3034
    • (2010) Clin. Cancer Res. , vol.16 , pp. 3028-3034
    • Dorff, T.B.1    Goldman, B.2    Pinski, J.K.3    Mack, P.C.4    Lara, P.N.5    Van Veldhuizen, P.J.6
  • 100
    • 84919683208 scopus 로고    scopus 로고
    • A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma
    • R.Z. Orlowski, L. Gercheva, C. Williams, H. Sutherland, T. Robak, T. Masszi, and et al. A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma Am. J. Hematol. 90 2015 42 49
    • (2015) Am. J. Hematol. , vol.90 , pp. 42-49
    • Orlowski, R.Z.1    Gercheva, L.2    Williams, C.3    Sutherland, H.4    Robak, T.5    Masszi, T.6
  • 102
    • 69249087671 scopus 로고    scopus 로고
    • Environment-mediated drug resistance: A major contributor to minimal residual disease
    • M.B. Meads, R.A. Gatenby, and W.S. Dalton Environment-mediated drug resistance: a major contributor to minimal residual disease Nat. Rev. Cancer 9 2009 665 674
    • (2009) Nat. Rev. Cancer , vol.9 , pp. 665-674
    • Meads, M.B.1    Gatenby, R.A.2    Dalton, W.S.3
  • 103
  • 104
    • 70349402169 scopus 로고    scopus 로고
    • Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): Evidence of safety and efficacy in a 5-year extension study
    • N. Nishimoto, N. Miyasaka, K. Yamamoto, S. Kawai, T. Takeuchi, and J. Azuma Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study Ann. Rheum. Dis. 68 2009 1580 1584
    • (2009) Ann. Rheum. Dis. , vol.68 , pp. 1580-1584
    • Nishimoto, N.1    Miyasaka, N.2    Yamamoto, K.3    Kawai, S.4    Takeuchi, T.5    Azuma, J.6
  • 105
    • 84891795508 scopus 로고    scopus 로고
    • Effectiveness and safety of tocilizumab: Postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan
    • T. Koike, M. Harigai, S. Inokuma, N. Ishiguro, J. Ryu, T. Takeuchi, and et al. Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan J. Rheumatol. 41 2014 15 23
    • (2014) J. Rheumatol. , vol.41 , pp. 15-23
    • Koike, T.1    Harigai, M.2    Inokuma, S.3    Ishiguro, N.4    Ryu, J.5    Takeuchi, T.6
  • 106
    • 28644436100 scopus 로고    scopus 로고
    • Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains
    • J. Silverman, Q. Liu, A. Bakker, W. To, A. Duguay, B.M. Alba, and et al. Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains Nat. Biotechnol. 23 2005 1556 1561
    • (2005) Nat. Biotechnol. , vol.23 , pp. 1556-1561
    • Silverman, J.1    Liu, Q.2    Bakker, A.3    To, W.4    Duguay, A.5    Alba, B.M.6
  • 109
    • 84907938432 scopus 로고    scopus 로고
    • Mutational approaches to improve the biophysical properties of human single-domain antibodies
    • D.Y. Kim, G. Hussack, H. Kandalaft, and J. Tanha Mutational approaches to improve the biophysical properties of human single-domain antibodies Biochim. Biophys. Acta 1844 2014 1983 2001
    • (2014) Biochim. Biophys. Acta , vol.1844 , pp. 1983-2001
    • Kim, D.Y.1    Hussack, G.2    Kandalaft, H.3    Tanha, J.4
  • 110
    • 80051668855 scopus 로고    scopus 로고
    • Whole-molecule antibody engineering: Generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics
    • D.K. Finch, M.A. Sleeman, J. Moisan, F. Ferraro, S. Botterell, J. Campbell, and et al. Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics J. Mol. Biol. 411 2011 791 807
    • (2011) J. Mol. Biol. , vol.411 , pp. 791-807
    • Finch, D.K.1    Sleeman, M.A.2    Moisan, J.3    Ferraro, F.4    Botterell, S.5    Campbell, J.6
  • 112
    • 84896996881 scopus 로고    scopus 로고
    • Chemically modified DNA aptamers bind interleukin-6 with high affinity and inhibit signaling by blocking its interaction with interleukin-6 receptor
    • S. Gupta, M. Hirota, S.M. Waugh, I. Murakami, T. Suzuki, M. Muraguchi, and et al. Chemically modified DNA aptamers bind interleukin-6 with high affinity and inhibit signaling by blocking its interaction with interleukin-6 receptor J. Biol. Chem. 289 2014 8706 8719
    • (2014) J. Biol. Chem. , vol.289 , pp. 8706-8719
    • Gupta, S.1    Hirota, M.2    Waugh, S.M.3    Murakami, I.4    Suzuki, T.5    Muraguchi, M.6
  • 113
    • 84901649576 scopus 로고    scopus 로고
    • Hyaluronate-gold nanoparticle/tocilizumab complex for the treatment of rheumatoid arthritis
    • H. Lee, M.Y. Lee, S.H. Bhang, B.S. Kim, Y.S. Kim, J.H. Ju, and et al. Hyaluronate-gold nanoparticle/tocilizumab complex for the treatment of rheumatoid arthritis ACS Nano 8 2014 4790 4798
    • (2014) ACS Nano , vol.8 , pp. 4790-4798
    • Lee, H.1    Lee, M.Y.2    Bhang, S.H.3    Kim, B.S.4    Kim, Y.S.5    Ju, J.H.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.